Oral immunization with recombinant enterovirus 71 VP1 formulated with chitosan protects mice against lethal challenge

Virology Journal

Volumn 11, Issue 1, 2014, Pages

  Zhang, Fushun ^a   Hao, Chunsheng ^b   Zhang, Shuo ^a   Li, Aqian ^a   Zhang, Quanfu ^a   Wu, Wei ^a   Liu, Lin ^a   Li, Chuan ^a   Liang, Mifang ^a   Li, Xiuling ^b   Li, Dexin ^a  

^a National Institute for Viral Disease Control and Prevention   (China)

^b Beijing Institute of Biological Products Co Ltd   (China)

Author keywords

Enterovirus 71; Oral immunization; Virus challenge; VP1

Indexed keywords

CHITOSAN; GAMMA INTERFERON; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INTERLEUKIN 4; NEUTRALIZING ANTIBODY; PROTEIN VP1; RECOMBINANT PROTEIN; RECOMBINANT VP1 PROTEIN; SUBUNIT VACCINE; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; VIRUS VACCINE; CYTOKINE; IMMUNOLOGICAL ADJUVANT; RECOMBINANT VACCINE; VIRUS ANTIBODY; VIRUS PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ARTICLE; CELL LEVEL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; ENTEROVIRUS 71; ENTEROVIRUS 71 INFECTION; ENTEROVIRUS INFECTION; FECES; FEMALE; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; INTERFERON PRODUCTION; INTESTINE; MOUSE; MUCOSAL IMMUNITY; NEWBORN; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN CONTENT; RESPIRATORY SYSTEM; SPLEEN CELL; SURVIVAL RATE; TREATMENT OUTCOME; VAGINA; VIRUS IMMUNITY; ANIMAL; BLOOD; DISEASE MODEL; ENTEROVIRUS; ENTEROVIRUS INFECTIONS; GENETICS; IMMUNOLOGY; INSTITUTE FOR CANCER RESEARCH MOUSE; MONONUCLEAR CELL; ORAL DRUG ADMINISTRATION; PROCEDURES; SECRETION (PROCESS); SPLEEN; SURVIVAL; VACCINATION;

HUMAN ENTEROVIRUS 71; MIRIDAE; MUS;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, ORAL; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CHITOSAN; CYTOKINES; DISEASE MODELS, ANIMAL; ENTEROVIRUS A, HUMAN; ENTEROVIRUS INFECTIONS; FEMALE; IMMUNITY, MUCOSAL; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; LEUKOCYTES, MONONUCLEAR; MICE, INBRED ICR; RECOMBINANT PROTEINS; SPLEEN; SURVIVAL ANALYSIS; VACCINATION; VACCINES, SYNTHETIC; VIRAL STRUCTURAL PROTEINS; VIRAL VACCINES;

EID: 84901002618     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-11-80     Document Type: Article

References (23)

1. Enterovirus 71 outbreak in the People's Republic of China in 2008. Yang F, Ren L, Xiong Z, Li J, Xiao Y, Zhao R, He Y, Bu G, Zhou S, Wang J, Qi J, J Clin Microbiol 2009 47 2351 2352 10.1128/JCM.00563-09 19439545
2. An epidemic of enterovirus 71 infection in Taiwan. Taiwan Enterovirus Epidemic Working Group. Ho M, Chen ER, Hsu KH, Twu SJ, Chen KT, Tsai SF, Wang JR, Shih SR, N Engl J Med 1999 341 929 935 10.1056/NEJM199909233411301 10498487 (Pubitemid 29441546)
3. Temperature-sensitive mutants of enterovirus 71 show attenuation in cynomolgus monkeys. Arita M, Shimizu H, Nagata N, Ami Y, Suzaki Y, Sata T, Iwasaki T, Miyamura T, J Gen Virol 2005 86 1391 1401 10.1099/vir.0.80784-0 15831951 (Pubitemid 40613257)
4. Immunity to avirulent enterovirus 71 and coxsackie A16 virus protects against enterovirus 71 infection in mice. Wu TC, Wang YF, Lee YP, Wang JR, Liu CC, Wang SM, Lei HY, Su IJ, Yu CK, J Virol 2007 81 10310 10315 10.1128/JVI.00372-07 17626076 (Pubitemid 47463306)
5. Formaldehyde-inactivated whole-virus vaccine protects a murine model of enterovirus 71 encephalomyelitis against disease. Ong KC, Devi S, Cardosa MJ, Wong KT, J Virol 2010 84 661 665 10.1128/JVI.00999-09 19864378
6. Protection against lethal enterovirus 71 infection in newborn mice by passive immunization with subunit VP1 vaccines and inactivated virus. Wu CN, Lin YC, Fann C, Liao NS, Shih SR, Ho MS, Vaccine 2001 20 895 904 10.1016/S0264-410X(01)00385-1 11738755 (Pubitemid 34015831)
7. Immunization with virus-like particles of enterovirus 71 elicits potent immune responses and protects mice against lethal challenge. Chung YC, Ho MS, Wu JC, Chen WJ, Huang JH, Chou ST, Hu YC, Vaccine 2008 26 1855 1862 10.1016/j.vaccine.2008.01.058 18329759
8. DNA vaccine constructs against enterovirus 71 elicit immune response in mice. Tung WS, Bakar SA, Sekawi Z, Rosli R, Genet Vaccines Ther 2007 5 6 10.1186/1479-0556-5-6 17445254
9. Epithelial M cells: gateways for mucosal infection and immunization. Neutra MR, Frey A, Kraehenbuhl JP, Cell 1996 86 345 348 10.1016/S0092-8674(00) 80106-3 8756716 (Pubitemid 26272074)
10. Cross-protection against influenza virus infection by intranasal administration of M1-based vaccine with chitosan as an adjuvant. Sui Z, Chen Q, Fang F, Zheng M, Chen Z, Vaccine 2010 28 7690 7698 10.1016/j.vaccine.2010.09.019 20870054
11. The immune response induced by H pylori vaccine with chitosan as adjuvant and its relation to immune protection. Xie Y, Zhou NJ, Gong YF, Zhou XJ, Chen J, Hu SJ, Lu NH, Hou XH, World J Gastroenterol 2007 13 1547 1553 17461447 (Pubitemid 46672663)
12. Identification of human CD4 T-cell epitopes on the VP1 capsid protein of enterovirus 71. Foo DG, Macary PA, Alonso S, Poh CL, Viral Immunol 2008 21 215 224 10.1089/vim.2007.0089 18419256 (Pubitemid 351873363)
13. Identification of neutralizing linear epitopes from the VP1 capsid protein of Enterovirus 71 using synthetic peptides. Foo DG, Alonso S, Phoon MC, Ramachandran NP, Chow VT, Poh CL, Virus Res 2007 125 61 68 10.1016/j.virusres. 2006.12.005 17222936 (Pubitemid 46413387)
14. Sambrook J, Russell DW, Molecular cloning: a laboratory manual New York: Cold Spring Harbor Laboratory Press 2001
15. [Generation of recombinant human antibodies for EV71 virus]. Sun LN, Zhang L, Zhang FS, Li C, Zhang QF, Li DX, Liang MF, Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi 2011 25 161 163 21977579
16. Effect of dietary cyclic nigerosylnigerose on intestinal immune functions in mice. Hino K, Kurose M, Sakurai T, Inoue S, Oku K, Chaen H, Kohno K, Fukuda S, Biosci Biotechnol Biochem 2006 70 2481 2487 10.1271/bbb.60215 17031050 (Pubitemid 44656415)
17. Oral immunization of mice using transgenic tomato fruit expressing VP1 protein from enterovirus 71. Chen HF, Chang MH, Chiang BL, Jeng ST, Vaccine 2006 24 2944 2951 10.1016/j.vaccine.2005.12.047 16448730
18. Interaction of antigens and antibodies at mucosal surfaces. Lamm ME, Annu Rev Microbiol 1997 51 311 340 10.1146/annurev.micro.51.1.311 9343353 (Pubitemid 27433052)
19. The common mucosal immune system and current strategies for induction of immune responses in external secretions. Mestecky J, J Clin Immunol 1987 7 265 276 10.1007/BF00915547 3301884 (Pubitemid 17146794)
20. Local secretory immunoglobulin A and postimmunization gastritis correlate with protection against Helicobacter pylori infection after oral vaccination of mice. Goto T, Nishizono A, Fujioka T, Ikewaki J, Mifune K, Nasu M, Infect Immun 1999 67 2531 2539 10225917 (Pubitemid 29200515)
21. Modulation of immune response to group C meningococcal conjugate vaccine given intranasally to mice together with the LTK63 mucosal adjuvant and the trimethyl chitosan delivery system. Baudner BC, Morandi M, Giuliani MM, Verhoef JC, Junginger HE, Costantino P, Rappuoli R, Del GG, J Infect Dis 2004 189 828 832 10.1086/381708 14976599 (Pubitemid 38328183)
22. The concomitant use of the LTK63 mucosal adjuvant and of chitosan-based delivery system enhances the immunogenicity and efficacy of intranasally administered vaccines. Baudner BC, Giuliani MM, Verhoef JC, Rappuoli R, Junginger HE, Giudice GD, Vaccine 2003 21 3837 3844 10.1016/S0264-410X(03)00305- 0 12922117 (Pubitemid 37338211)
23. Immune stimulating activity of two new chitosan containing adjuvant formulations. Seferian PG, Martinez ML, Vaccine 2000 19 661 668 10.1016/S0264-410X(00)00248-6 11090719